careers HOME ABOUT US RESEARCH NEWS EVENTS home about us pipeline investors research news events sitemap contact SITEMAP CONTACT US CAREERS PIPELINE DEVELOPMENT PIPELINE
THERAPEUTIC FOCUS
NEWS
BIONOR IMMUNO IS PRESENTING...
Bionor Immuno is an active presenter at different events.
Bionor Immuno is a multidisciplinary biomedical drug development company with a well-established platform technology for the devlopment of therapeutic and preventative vaccines for infectous disseases using a modified peptide-based approach.
QUICKLINKS
© 2008 BionorImmuno, Inc. All rights Reserved
Bionor Immuno AS, a subsidary of Bionor Pharma ASA was established on July 14th 2000 as a spin off from the R&D on immune based therapies that until then had been performed by its sister company, Bionor AS. Both companies are located at the Telemark Biomedical Centre, Skien, Norway together with two of its development partners AS Telelab and Mericon AS.
March 2010: Bionor Immuno will take the therapeutic and potentially preventative HIV-vaccine candidate Vacc-C5 towards phase I/II clinical trial.
MORE INFO...BIONOR IMMUNO IS WORKING TO MAKE A DIFFERENCE FOR PATIENTS WITH INFECTIOUS DISEASES AND CANCER
INVESTORS Vacc-4x Shows Response Seven Years after InoculationJuly 2010: Results from a recently conducted re-vaccination study at Ullevål University Hospital, Oslo, Norway, using Vacc-4x were presented at the AIDS conference in Vienna
Vacc-C5 to be prepared for phase I/II clinical trial "Current Opinion in Investigational Drugs"August 2010: Thomson Reuters' Current Opinion in Investigational Drugs is published monthly and delivers systematic and comprehensive coverage of the following therapeutic areas: Anti-infectives; Anti-inflammatory, immune-meditated and gastrointestinal; Cardiovascular, renal and metabolic; Central and peripheral nervous system; Oncological
Independent research report on Bionor published in Thomson Reuters'Novel Science – Benefits Patients
THERAPEUTIC FOCUS
NEWS
BIONOR IMMUNO IS PRESENTING...
Bionor Immuno is an active presenter at different events.
Bionor Immuno is a multidisciplinary biomedical drug development company with a well-established platform technology for the devlopment of therapeutic and preventative vaccines for infectous disseases using a modified peptide-based approach.
QUICKLINKS
© 2008 BionorImmuno, Inc. All rights Reserved
Bionor Immuno AS, a subsidary of Bionor Pharma ASA was established on July 14th 2000 as a spin off from the R&D on immune based therapies that until then had been performed by its sister company, Bionor AS. Both companies are located at the Telemark Biomedical Centre, Skien, Norway together with two of its development partners AS Telelab and Mericon AS.
March 2010: Bionor Immuno will take the therapeutic and potentially preventative HIV-vaccine candidate Vacc-C5 towards phase I/II clinical trial.
MORE INFO...BIONOR IMMUNO IS WORKING TO MAKE A DIFFERENCE FOR PATIENTS WITH INFECTIOUS DISEASES AND CANCER
INVESTORS Vacc-4x Shows Response Seven Years after InoculationJuly 2010: Results from a recently conducted re-vaccination study at Ullevål University Hospital, Oslo, Norway, using Vacc-4x were presented at the AIDS conference in Vienna
Vacc-C5 to be prepared for phase I/II clinical trial "Current Opinion in Investigational Drugs"August 2010: Thomson Reuters' Current Opinion in Investigational Drugs is published monthly and delivers systematic and comprehensive coverage of the following therapeutic areas: Anti-infectives; Anti-inflammatory, immune-meditated and gastrointestinal; Cardiovascular, renal and metabolic; Central and peripheral nervous system; Oncological
Independent research report on Bionor published in Thomson Reuters'Novel Science – Benefits Patients